DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway

WUBIN GUO1,2, HUI LI1, HUAN LIU3, XIN MA2, SIJIN YANG4 and ZIWEI WANG1

1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016; 2Department of General Surgery, 3Research Laboratory of Biomedical Engineering and 4Department of Cardiovascular Medicine, The TCM Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China

Received January 14, 2019; Accepted July 3, 2019

DOI: 10.3892/or.2019.7221

Abstract. DEP domain containing 1 (DEPDC1) functions as an oncogene in hepatocellular carcinoma (HCC). However, the underlying mechanism of DEPDC1 remains largely unknown. The present study revealed that DEPDC1 knockdown inhibited HCC cell proliferation, colony formation and invasion in vitro and suppressed the growth of HCC xenografts in vivo. Furthermore, DEPDC1 overexpression promoted HCC cell proliferation, colony formation and invasion. DNA microarray, reverse transcription-quantitative-PCR and western blotting results demonstrated that DEPDC1 knockdown in Huh-7 significantly inhibited the expression of chemokine (C-C motif) ligand 20 (CCL20) and chemokine (C-C motif) receptor 6 (CCR6). In addition, the expression of CCL20 and CCR6 were upregulated in HCC tissues and cell lines, and were positively correlated with DEPDC1 expression. CCL20 or CCR6 knockdown via small interfering RNA reversed the effects of DEPDC1 overexpression in HCC cells. Furthermore, it was revealed that conditioned medium from DEPDC1 upregulated Li-7 and Hep3B cells led to angiogenesis in vitro, whereas CCL20 knockdown in Li-7 and Hep3B cells or CCR6 knockdown in human umbilical vein endothelial cells reversed the angiogenic effect of DEPDC1 overexpression. In conclusion, DEPDC1 facilitated cell proliferation, invasion and angiogenesis via the CCL20/CCR6 pathway in HCC.

Introduction

Hepatocellular carcinoma (HCC) is a highly lethal cancer with an increasing incidence, making it a cause of major health problems worldwide (1,2). Recently, surgical treatments including hepatic resection, liver transplantation, local ablative therapy and transarterial chemoembolization have been the most successful approaches to HCC. Patients with HCC have benefitted from significant improvements in tumor identification and patient survival (3,4). However, the incidence rate of HCC is almost equivalent to its mortality rate in most countries, indicating a lack of early diagnostic methods and effective therapies (5). Therefore, studies that identify novel factors involved in HCC oncogenesis are essential for the improvement of early diagnosis and therapeutic approaches.

The DEP domain containing 1 (DEPDC1) gene is a highly conserved protein that is located at 1p31.3. It is primarily expressed in the testis and is not detected in other normal human tissues (6). Recently, several studies revealed that DEPDC1 was upregulated in many tumor types, indicating its important role in tumorigenesis (7-10). For example, DEPDC1 was upregulated in bladder carcinogenesis and the inhibition of DEPDC1 via small-interfering RNA (siRNA) significantly suppressed the growth of bladder cancer cells (7). In nasopharyngeal carcinoma, DEPDC1 was overexpressed in tumor tissues and DEPDC1 depletion induced the inhibition of cell proliferation, migration and invasion (9). Thus, DEPDC1 usually functions as an oncogene. In addition, HCC has been determined to overexpress DEPDC1, which is associated with a poor prognosis (11). A previous study revealed that disrupting the DEPDC1-ZNF224 complex via the 1R-DEP peptide induced apoptosis and inhibited the proliferation of HepG2 cells (12). Qu et al (13) demonstrated that DEPDC1 upregulation induced HCC cell proliferation and neoplasm metastasis. The present study revealed that DEPDC1 knockdown significantly suppressed HCC cell proliferation, colony formation and invasion, and DEPDC1 overexpression significantly induced HCC cell proliferation, colony formation and invasion. However, the role and precise mechanism of DEPDC1 in HCC is still not fully understood.
The aim of the present study was to elucidate the underlying mechanism of DEPDC1 in HCC. After a DNA microarray assay was performed, Gene ontology (GO) annotation results revealed that DEPDC1 was involved in vasculature development and blood vessel development. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed cytokine-cytokine receptor interactions were significantly enriched. DNA microarray, reverse transcription-quantitative PCR (RT-qPCR) and western blotting results revealed that DEPDC1 knockdown significantly suppressed the expression of chemokine (C-C motif) ligand 20 (CCL20) and chemokine (C-C motif) receptor 6 (CCR6). Recently, the CCL20/CCR6 axis has been determined to be involved in HCC cell growth and invasion (14,15). Additionally, Benkheil et al (16) revealed that the CCL20/CCR6 axis contributed to hepatic angiogenesis in hepatitis C virus (HCV)-associated HCC. Angiogenesis is vital for the growth of cancer and the development of metastasis (17). Thus, the CCL20/CCR6 axis may serve an important role in DEPDC1-mediated HCC progression. Based on the aforementioned hypothesis, the present study further investigated the role of the CCL20/CCR6 axis in DEPDC1-mediated HCC progression, which may elucidate a novel mechanism of DEPDC1 in HCC.

Materials and methods

Ethics statement. The present study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). All animal experiments were performed as indicated in the Guidelines of the National Institutes of Health for Animal Care (Guide for the Care and Use of Laboratory Animals, Department of Health and Human Services, NIH publication no. 86-23, revised 1985).

Human tissues. A total of 12 pairs of tumor tissue with matched adjacent normal tissue were obtained from patients diagnosed with HCC at the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) between October 2016 and July 2017. The patients comprised of 10 men and 2 women from 45 to 73 years of age. All patients provided their written informed consent. None of the patients had received radiotherapy, immunotherapy or chemotherapy prior to surgery. All tissue samples were frozen in liquid nitrogen and subsequently stored at -80°C for RT-qPCR analysis.

Immunohistochemistry (IHC). IHC examination of DEPDC1, CCL20 and CCR6 was performed as previously described (18). HCC tissues embedded in paraffin were cut into 4-µm-thick sections. Sections were then subjected to de-waxing and rehydration, after which antigen retrieval was performed via microwave treatment for 15 min. Sections were subsequently treated with 3% hydrogen peroxide for 15 min to block endogenous peroxidase activity and incubated with 10% goat non-immune serum for 30 min. Sections were incubated with the following antibodies overnight at 4°C: Rabbit anti-human DEPDC1 (1:50; cat. no. GTX17614; GeneTex, Inc.), rabbit anti-human CCL20 (1:200; cat. no. 26527-1-AP; Proteintech Group, Inc.) and rabbit anti-human CCR6 (1:1,000; cat. no. ab227036; Abcam). Sections were then incubated with corresponding goat anti-rabbit secondary antibody (dilution 1:500; cat. no. SA00004-2; Proteintech Group, Inc.) at room temperature for 1 h. Freshly prepared 3,3'-diaminobenzidine (DAB) from a DAB Substrate kit (Abcam) was added for color development. IHC scoring was performed as previously described (18). Staining intensity was graded on a 0-3 scale as follows: 0, absence of staining; 1, weak staining; 2, moderate staining; 3, strong staining. The percentage of positive tumor cells was scored as follows: 0, absence of tumor cells; 1, <33% positive tumor cells; 2, 33-66% positive tumor cells; 3, >66% tumor cells. The IHC score (0-9) was calculated by multiplying the staining intensity by the percentage scores.

Cell culture. L02 cells were purchased from Xiangya Central Experiment Laboratory (Changsha, China). Li-7, Huh-7, SNU-387 and Hep3B cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Human umbilical vein endothelial cells (HUVECs) were purchased from the China Center for Typical Culture Collection. L02, SNU-387 and Li-7 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). Huh-7 cells were cultured in DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) containing 10% FBS. Hep3B cells were cultured in Minimum Essential medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% FBS.

siRNA, plasmids, cell grouping and transfection. The full-length clone DNA of human DEPDC1 (NM_001114210.3; 2,436 bp) was obtained from FulenGen and subsequently cloned into the pcDNA3.1 plasmid vector by SunBio (Shanghai, China). DEPDC1 siRNA, CCL20 siRNA, CCR6 siRNA and the scrambled negative control (NC) used in this study were designed and synthesized by Shanghai GenePharma Co., Ltd. DEPDC1 short hairpin RNA (DEPDC1 shRNA) and scrambled negative shRNA (shNC) were designed, synthesized and cloned into the pMAGic1.1 plasmid vector by SunBio (Shanghai, China). The sequences of siRNA and shRNA are listed in Table I.

To determine the effects of DEPDC1 downregulation, Huh-7 and SNU-387 cells were divided to two groups: A scrambled NC group and a DEPDC1 siRNA group. Huh-7 and SNU-387 cells (3x10^5 cells/2 ml) were seeded into 6-well plates. When cells reached 70-90% confluence, they were transfected. A total of 30 pmol NC or DEPDC1 siRNA with 7.5 µl Lipofectamine® RNAiMAX reagent (Invitrogen; Thermo Fisher Scientific, Inc.) in 250 µl Opti-MEM® medium was added into each well. After 6 h, the transfection medium was replaced with DMEM or RPMI-1640 medium. Further analyses were performed after incubation for 72 h.

To generate a stable DEPDC1-suppressed Huh-7 cell line, Huh-7 cells were transfected with the shNC and DEPDC1 shRNA plasmid vectors. Huh-7 cells (3x10^5 cells/2 ml) were seeded into 6-well plates. When cells reached 70-90% confluence, 2.5 µg shNC or DEPDC1 shRNA with 8 µl Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) in 250 µl Opti-MEM® medium was added into each well. After 8 h, the transfection medium was replaced with DMEM. After 72 h, the cells were selected using 6 µg/ml puromycin for 4 weeks.
To assess the effect of DEPDC1 upregulation, Li-7 and Hep3B cells were divided into two groups: A pcDNA3.1 control group (pcDNA3.1) and a pcDNA3.1 DEPDC1 expression vector group (DEPDC1). Li-7 and Hep3B cells (3x10⁵ cells/2 ml) were seeded into 6-well plates. When the cells reached 70-90% confluence, 2.5 µg pcDNA3.1 or DEPDC1 plasmids with 8 µl Lipofectamine® 2000 reagent in 250 µl Opti-MEM® medium were added into each well. After 8 h, the transfection medium was replaced with RPMI-1640 medium or MEM. Further analyses were performed after incubation for 72 h.

For rescue experiments, Li-7 and Hep3B cells were divided into four groups: Cells co-transfected with pcDNA3.1 control vectors and the scrambled negative control (pcDNA3.1+NC group); cells co-transfected with DEPDC1 expression vectors and the scrambled negative control (DEPDC1+NC group); cells co-transfected with DEPDC1 expression vectors and CCL20 siRNA (DEPDC1+CCL20 siRNA group); and cells co-transfected with DEPDC1 expression vectors and CCR6 siRNA (DEPDC1+CCR6 siRNA group). Li-7 and Hep3B cells (3x10⁵ cells/2 ml) were seeded into 6-well plates. When the cells reached 70-90% confluence, 75 pmol NC, CCL20 siRNA or CCR6 siRNA in addition to 2.5 µg pcDNA3.1 control vectors or DEPDC1 expression vectors in 250 µl Opti-MEM® medium were added into each well. After 8 h, the transfection medium was replaced with RPMI-1640 medium or MEM. Further analyses were performed after incubation for 72 h.

Western blotting. After treatment, cells were collected and lysed with ice-cold RIPA lysis buffer (cat. no. AR0105; Wuhan Boster Biological Technology, Ltd.). The cell suspension was centrifuged at 12,000 x g for 15 min, and the supernatant was aspirated and placed in a fresh tube. A bicinchoninic acid protein concentration assay kit (cat. no. AR0146; Wuhan Boster Biological Technology, Ltd.) was used to determine the protein concentration of each cell lysate. Total protein (30 µg) from each cell lysate was adjusted to an equal volume using loading buffer and denatured at 100 °C for 5 min. Each cell sample was separated via 10% SDS-PAGE and subsequently electro-transferred to PVDF membranes (cat. no. AR0136-04; Wuhan Boster Biological Technology, Ltd.). The membranes were then blocked with 5% non-fat milk for 1 h at room temperature. The membranes were then incubated with the following primary antibodies overnight at 4 °C: Rabbit anti-human DEPDC1 (dilution 1:500; cat. no. PA5-34864) and goat anti-human CCL20 (dilution 1:2,000; cat. no. PA5-47517; both from Invitrogen; Thermo Fisher Scientific, Inc.), rabbit anti-human CCR6 (dilution 1:1,000; cat. no. ab227036; Abcam), rabbit anti-human p-AKT (dilution 1:1,500; cat. no. P00024-6; Wuhan Boster Biological Technology, Ltd.), rabbit anti-human AKT (dilution 1:1,000; Table I. The sequences of siRNA, shRNA and RT-qPCR primers.

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEPDC1 siRNA sense</td>
<td>5'-UCAGAACAAUUCGCAGAUUAAUUUTT-3'</td>
</tr>
<tr>
<td>DEPDC1 siRNA antisense</td>
<td>5'-AAUAUACUGCAUGUUGUUGATT-3'</td>
</tr>
<tr>
<td>CCR6 siRNA sense</td>
<td>5'-GACCAGUGAGACGCAGAUAAAT-3'</td>
</tr>
<tr>
<td>CCR6 siRNA antisense</td>
<td>5'-UUUCUGACGUGACCUUATTC-3'</td>
</tr>
<tr>
<td>NC sense</td>
<td>5'-UCUCUCGGAAAGUGUACGUTT-3'</td>
</tr>
<tr>
<td>NC antisense</td>
<td>5'-ACGUGACACGUGAGAGAT-3'</td>
</tr>
<tr>
<td>DEPDC1 shRNA sense</td>
<td>5'-CCGGGTCAAGAACAAATCCAGATATTTCCTGAGAAATAATCTCGAATTGTGATT-3'</td>
</tr>
<tr>
<td>DEPDC1 shRNA antisense</td>
<td>5'-AATTCAAAAACCGGTCAAGAACAATCCAGATATTTCCTGAGAAATAATCTCGAATTGTGATT-3'</td>
</tr>
<tr>
<td>shNC sense</td>
<td>5'-CCGTTTCTCCAGAAGCTGTCAGTTTTCAAGAGAAGCAGGTTCCGAGAGAAT -3'</td>
</tr>
<tr>
<td>shNC antisense</td>
<td>5'-AAATCTTAACTTCCAGAAGCTGTCAGTTTTCAAGAGAAGCAGGTTCCGAGAGAAT -3'</td>
</tr>
<tr>
<td>DEPDC1 forward</td>
<td>5'-CCGAAACATAGAAGGACAAACAA-3'</td>
</tr>
<tr>
<td>DEPDC1 reverse</td>
<td>5'-CTCTTTGGTCGGACAGGT-3'</td>
</tr>
<tr>
<td>β-actin forward</td>
<td>5'-CATGTAACGTTGCTATCCAGCC-3'</td>
</tr>
<tr>
<td>β-actin reverse</td>
<td>5'-CTCTTAACTGTCAGCGAAGAT-3'</td>
</tr>
<tr>
<td>CCL20 forward</td>
<td>5'-CTCTTTGCGCTTGGTTGATAGTC-3'</td>
</tr>
<tr>
<td>CCL20 reverse</td>
<td>5'-ATTTCGACACAGACAAACT-3'</td>
</tr>
<tr>
<td>CCR6 forward</td>
<td>5'-CCTGAGGAAATCTTGTTGTTGTA-3'</td>
</tr>
<tr>
<td>CCR6 reverse</td>
<td>5'-CATGCGTAGCTTTTGGTTGTTAT-3'</td>
</tr>
</tbody>
</table>

DEPDC1, DEP domain containing 1; siRNA, small interfering RNA; CCR6, chemokine (C-C motif) receptor 6; NC, negative control; shRNA, short hairpin RNA; shNC, short hairpin NC; CCL20, chemokine (C-C motif) ligand 20.
cat. no. 10176-2-AP), rabbit anti-human c-myc (dilution 1:2,000; cat. no. 10828-1-AP), rabbit anti-human cyclin E1 (dilution 1:1,000; cat. no. 11554-1-AP) and mouse anti-human β-actin (dilution 1:5,000; cat. no. 66009-1-Ig; all from ProteinTech Group, Inc.). After incubation, the membranes were washed three times with TBST and incubated with horseradish peroxidase (HRP)-conjugated AffiniPure goat anti-rabbit (dilution 1:5,000; cat. no. SA00001-2; ProteinTech Group, Inc.), HRP-conjugated AffiniPure rabbit anti-goat (dilution 1:5,000; cat. no. SA00001-4; ProteinTech Group, Inc.) and HRP-conjugated AffiniPure goat anti-mouse (dilution 1:5,000; cat. no. SA00001-1; ProteinTech Group, Inc.) at room temperature for 1 h. After incubation, the membranes were washed three times with TBST. Protein bands were visualized using an enhanced chemiluminescence substrate (cat. no. 17050; Thermo Fisher Scientific, Inc.) and horseradish peroxidase (HRP)-conjugated AffiniPure goat anti-mouse (dilution 1:5,000; cat. no. SA00001-2; ProteinTech Group, Inc.) at room temperature for 1 h. After incubation, the membranes were washed three times with TBST.

**RT-qPCR.** Total RNA was isolated from tissues and cultured cells using RNAiso Plus (cat. no. 9108; Takara Biotechnology Co., Ltd.) in accordance with the manufacturer’s protocol. Sample integrity and purity was analyzed via agarose gel electrophoresis and the value of A260/A280. RT was performed using M-MLV-RTase (cat. no. M1705; Promega Corporation) at 42˚C for 1 h with an 11-µl system (4 µl 5xRT buffer, 2 µl 10 mM dNTPs, 0.5 µl RNasin, 1 µl M-MLV-RTase and 3.5 µl DEPC-H2O). The expression of target genes was analyzed using SYBR Master Mixture (cat. no. DRR041B; Takara Biotechnology Co., Ltd.). The thermocycling conditions were as follows: Pre-denaturation for 15 sec at 95˚C, 45 cycles of denaturation for 5 sec at 95˚C, annealing at 60˚C for 30 sec and extension at 60˚C for 30 sec. The sequences of all primers used are presented in Table I. The relative expression of the target genes was normalized to β-actin using the 2−ΔΔCq analysis method (19).

**Cell viability assay.** After treatment, cells were inoculated in 96-well plates (1x104 cells/well) and further cultured for 1, 2, 3 or 4 days. Cell Counting Kit-8 solution (CCK-8; cat. no. C0038; Beyotime Institute of Biotechnology) was thawed in a water bath at 37˚C. A total of 10 µl CCK-8 solution was then added to each well of the plate. Cells were subsequently incubated for 2 h at 37˚C. After incubation, absorbance was measured at 450 nm using a microplate reader (Beckman Coulter, Inc.).

**EdU assay.** Cell proliferation was determined using the BeyoClick™ EdU Cell Proliferation kit with Alexa Fluor 594 (cat. no. C0078S; Beyotime Institute of Biotechnology). Cells were then washed with PBS and fresh medium (RPMI-1640 medium, DMEM or MEM) containing 10 µM EdU was added. Cells were subsequently incubated for 2 h at 37˚C in 5% CO2 and washed with PBS to remove the free EdU probe and medium. Cells were then fixed in 4% paraformaldehyde at room temperature for 15 min and stained with DAPI for 5 min. After an additional wash in PBS, positive cells were observed under a Olympus IX71 fluorescent microscope (Olympus Corp., Tokyo, Japan; magnification, x200) and analyzed using ImageJ software (version 1.43; National Institutes of Health). The mean numbers of EdU-positive cells were calculated from three images of each group (20).

**Colony formation assay.** After treatment, cells were seeded into 6-well plates (400 cells/well) and further cultured at 37˚C. After incubation for 14 days, the cells were washed with PBS, fixed with 4% paraformaldehyde at room temperature for 15 min, and stained with 0.2% crystal violet solution at room temperature for 20 min. The number of colonies was counted with an inverted fluorescence microscope (Nikon TE2000; Nikon Corp.).

**HCC cell invasion assay.** HCC cell invasion activities were determined using a 24-well Transwell chamber (cat. no. 3577; Corning Costar Corp.) with Matrigel (cat. no. 356234; BD Biosciences). After treatment, cells were seeded into the upper chamber of the Transwell equipment at a density of 1x105 cells per insert. A total of 500 µl of RPMI-1640, DMEM or MEM with 10% FBS was added to the lower chamber of the Transwell insert. After incubation for 48 h, cells remaining on the upper chamber of the Transwell insert were removed. Cells on the underside of the chamber were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. Invaded cells were subsequently counted under a microscope (magnification, x200) in six different fields of view for each sample.

**In vitro HUVEC tube formation assay.** Li-7 and Hep3B cells transfected with pcDNA3.1 or DEPDC1 expression vectors, or co-transfected with NC or CCL20 siRNA were further incubated for 72 h. Tumor cell-conditioned medium (TCM) was prepared as previously described (21,22). The medium was removed, and the cells were washed in triplicate with PBS. Serum-free RPMI-1640 medium or MEM was then added to each well of the plate. After incubation for 24 h, TCM was collected and stored at -80˚C. Prior to the tube formation assay, each well of a 96-well plate was pre-coated with Matrigel (cat. no. 3432-005-01; R&D Systems, Inc.). HUVECs or HUVECs pretreated with NC or CCR6 siRNA (2x104 cells/100 µl) were then added to each well of the plate. After incubation for 4 h, the branch points of the formed tubes were scanned under a inverted fluorescence microscope (Nikon TE2000; Nikon Corp.) and quantitated in at least 5 microscopic fields.

**HUVEC invasion assays.** HUVECs invasion activities were determined using a 24-well Transwell chamber (cat. no. 3577; Corning Costar Corp.) with Matrigel (cat. no. 356234; BD Biosciences). Cells (1x104) prepared in 400 µl serum-free media were seeded into the upper chamber of the Transwell insert. A total of 600 µl TCM was added to the lower chamber of the Transwell insert. After incubation for 48 h, the cells remaining in the upper chamber of the Transwell insert were removed. Cells on the underside of the chamber were fixed with 4% paraformaldehyde at room temperature for 30 min and stained with 0.1% crystal violet at room temperature for 20 min. Invaded cells were subsequently counted under a inverted fluorescence microscope (Nikon TE2000; Nikon Corp.) (magnification, x200) in six different fields of view for each sample.
**Nude mice tumour xenograft model.** BALB/c nude mice (n=5) at 4-5 weeks of age (weighing ~20 g) were obtained from Vital River Laboratories Co., Ltd., and randomly divided into two groups. All mice were maintained under specific pathogen-free conditions (temperature 25±1°C and relative humidity 60±10%) in laminar flow cabinets. All mice were housed with a 12-h light/dark cycle and autoclaved food/water was provided freely. The stable DEPDC1-suppressed Huh-7 cell line (DEPDC1 shRNA) and the shRNA control Huh-7 cell line (shNC; 2x10^6 cells/100 µl PBS) were inoculated subcutaneously in the left dorsal flank and the right flank of BALB/c nude mice, respectively. The width and length of the tumors were measured weekly and the volume was calculated using the following equation: (length x width^2)/2. After five weeks of injections, all mice were euthanized by CO2 asphyxiation and the tumors were excised.

**Microarray analysis.** Huh-7 cells were transfected with DEPDC1 siRNA or NC siRNA and further cultured for 72 h. After incubation, total RNA was isolated using the TRIzol Reagent (cat. no. 15596026; Invitrogen; Thermo Fisher Scientific, Inc.). The integrity and purity of RNA was analyzed via agarose gel electrophoresis and the value of A260/A280. cDNA was subsequently synthesized from total RNA and hybridized to the Affymetrix Gene Chip Human Gene 1.0 ST Array (cat. no. 901085; Affymetrix; Thermo Fisher Scientific, Inc.). Differentially expressed genes were analyzed using the Expression Console and Transcriptome Analysis Console v3.0 (Affymetrix; Thermo Fisher Scientific, Inc.). DAVID Bioinformatics Resources 6.7 (https://david.ncifcrf.gov/) was used to perform GO annotation and KEGG pathway analyses. Raw data has been deposited in the GEO database (GEO accession no. GSE122124).

**Statistical analysis.** All data were analyzed using IBM SPSS 21.0 software (IBM Corp.) and all experiments were repeated at least three times. Data were presented as the mean ± standard deviation. Significant differences between groups were determined using a Student's t-test or one-way analysis of variance (ANOVA) and Dunnett's multiple comparison post hoc test. The correlation between DEPDC1 and CCL20 or CCR6 expression in HCC tissue was determined via Pearson's correlation. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**DEPDC1 knockdown suppresses HCC tumourigenesis in vitro and in vivo.** To assess the molecular role of DEPDC1 in HCC, the expression of DEPDC1 was analyzed in four human HCC cell lines (Li-7, Huh-7, SNU-387 and Hep3B) and one normal human hepatic cell line (L02) via western blotting. The results revealed that DEPDC1 protein was primarily detected in HCC cell lines and a decreased expression was detected in L02 cells (Fig. 1A). Huh-7 and SNU-387 cells were transfected with a scrambled NC and DEPDC1 siRNA, the expression of DEPDC1 was determined by RT-qPCR and western blotting. As presented in Fig. 1B, DEPDC1 siRNA significantly suppressed DEPDC1 mRNA and protein expression. The results of the CCK-8 assay demonstrated that DEPDC1 knockdown significantly inhibited Huh-7 and SNU-387 cell viability (Fig. 1C). Following the EdU assay, a decreased number of EdU-positive cells were observed in Huh-7 and SNU-387 cells transfected with DEPDC1 siRNA compared with those transfected with the NC (Fig. 1D). The results of the colony formation and cell invasion assays revealed that DEPDC1 knockdown significantly inhibited colony formation and cell invasion in Huh-7 and SNU-387 cells (Fig. 1E and F).

**DEPDC1 upregulation promotes HCC cell progression.** To further confirm the molecular role of DEPDC1 in HCC, Li-7 and Hep3B cells were transfected with pcDNA3.1 and the pcDNA3.1 DEPDC1 expression vector. As presented in Fig. 2A, treatment with the DEPDC1 expression plasmid significantly upregulated DEPDC1 protein expression. The results of the CCK-8 assay demonstrated that DEPDC1 upregulation significantly induced Li-7 and Hep3B cell viability (Fig. 2B). Following the EdU assay, an increased number of EdU-positive cells were observed in Li-7 and Hep3B cells transfected with the pcDNA3.1 DEPDC1 expression vector compared with those transfected with the pcDNA3.1 control (Fig. 2C). The results of the colony formation and cell invasion assays revealed that DEPDC1 upregulation significantly increased colony formation and cell invasion in Li-7 and Hep3B cells (Fig. 2D and E).

**DEPDC1 downregulation affects gene expression at a global level.** To assess the possible mechanisms of DEPDC1 in HCC progression, microarray analysis was performed using RNA isolated from NC or DEPDC1 siRNA-transfected Huh-7 cells. As presented in Fig. 3A and B, a total of 129 genes were downregulated (fold change, <-2-fold) and 252 genes were upregulated (fold change, >2-fold). In addition, GO annotation and KEGG pathway analysis were performed using the DAVID Bioinformatics Resource 6.7 (https://david.ncifcrf.gov/). The results of GO analysis revealed that DEPDC1 was involved in C-X-C chemokine binding (Fig. 3C), vasculature development (Fig. 3D), blood vessel development (Fig. 3D) and extracellular matrix (Fig. 3E). KEGG pathway analysis determined that downregulated and upregulated genes significantly enriched in cytokine-cytokine receptor interaction (Fig. 3F). According to the functional results of DEPDC1, GO analysis and KEGG pathway analysis, the CCL20/CCR6 axis was selected for further study. In recent years, the CCL20/CCR6 axis has been implicated in the growth and invasion of HCC cells and in HCV-associated HCC hepatic angiogenesis (14-16). Thus, the CCL20/CCR6 axis may serve a vital role in the DEPDC1-mediated progression of HCC. RT-qPCR was performed to validate the expression of CCL20 and CCR6. In congruence with microarray results, the expression of CCL20 and CCR6 in Huh-7 cells treated with DEPDC1 siRNA was significantly lower compared with the NC group (Fig. 3G). In addition, DEPDC1 knockdown significantly inhibited the protein expression of CCL20 and CCR6 (Fig. 3H).
CCL20 and CCR6 expression is significantly increased in HCC tissue and cell lines. To verify the expression of DEPDC1, CCL20 and CCR6 mRNA in HCC tissue, RT-qPCR analysis was performed. The results revealed that DEPDC1, CCL20 and CCR6 mRNA was significantly upregulated in HCC tissue compared with matched adjacent normal liver tissue (Fig. 4A). In addition, CCL20 and CCR6 mRNA expression were positively correlated with that of DEPDC1 (Fig. 4B). Furthermore, IHC revealed that DEPDC1, CCL20 and CCR6 protein expression was significantly upregulated in HCC tissue compared with matched adjacent normal liver tissue (Fig. 4C and D). CCL20 and CCR6 protein expression were
also positively correlated with DEPDC1 protein expression (Fig. 4E). To determine whether CCL20 and CCR6 protein was also upregulated in HCC cell lines, western blotting was performed. As presented in Fig. 4F, CCL20 and CCR6 protein expression were significantly upregulated in four human HCC cell lines (Li-7, Huh-7, SNU-387 and Hep3B) when compared with L02 cells.

CCL20 or CCR6 knockdown by siRNA reverses the effect of DEPDC1 overexpression in HCC cells. To confirm the effect of DEPDC1 upregulation on CCL20 and CCR6, the protein expression of CCL20 and CCR6 in Li-7 and Hep3B cells transfected with pcDNA3.1 and DEPDC1 expression vectors were confirmed via western blotting. As presented in Fig. S1, DEPDC1 upregulation in Li-7 and Hep3B cells significantly induced CCL20 and CCR6 protein expression. Furthermore, CCL20 knockdown via siRNA reversed the effect of DEPDC1 overexpression on CCL20 and CCR6 expression in Li-7 and Hep3B cells (Fig. S2). Additionally, CCR6 knockdown via siRNA reversed the effect of DEPDC1 overexpression on the expression of CCR6 in Li-7 and Hep3B cells (Fig. S2). To ascertain whether DEPDC1 regulated HCC progression by mediating the CCL20/CCR6 axis, CCL20 and CCR6 were inhibited using siRNA in Li-7 and Hep3B cells transfected with DEPDC1 expression vectors. As presented in Fig. 5A, CCL20 or CCR6 knockdown reversed the increase in cell viability caused by DEPDC1 upregulation. In addition, the results revealed that CCL20 or CCR6 knockdown reversed the increase in the number of EdU-positive cells caused by DEPDC1 upregulation (Fig. 5B). As presented in Fig. 5C and D, CCL20 or CCR6 knockdown reversed the DEPDC1-mediated increase of colony formation and invasion. In normal breast cells, the CCL20/CCR6 axis may induce the expression of cell cycle-associated proteins (c-myc, c-Fos and cyclin E1) by inducing the activation of the PI3K/Akt pathway (23). The results of the present study revealed that DEPDC1 upregulation induced the expression of p-Akt, c-Myc and cyclin E1, while CCL20 or CCR6 knockdown reversed this effect (Fig. 5E).
DEPDC1 promotes HUVEC invasion and tube formation by regulating CCL20 in vitro. A capillary tube formation assay was performed in the present study to determine the biological significance of DEPDC1 in tumor angiogenesis. As presented in Fig. 6A and B, HUVECs incubated with TCM from DEPDC1-transfected Li-7 and Hep3B cells developed more capillary-like structures and displayed an increased invasive tendency compared with those cultured in pcDNA3.1-transfected TCM. To confirm whether DEPDC1 regulates HUVEC invasion and tube formation...
by mediating CCL20 activity, TCM was collected from Li-7 and Hep3B cells co-transfected with DEPDC1 expression vectors and CCL20 siRNA. The results demonstrated that CCL20 knockdown reversed the effect of DEPDC1 upregulation on HUVEC angiogenesis and invasion (Fig. 6A and B).

CCR6 knockdown in HUVECs reverses the effect of DEPDC1 overexpression on angiogenesis and invasion. It has been previously revealed that endothelial CCR6 serves an important role in CCL20-induced blood vessel formation and invasion induced in HCC (16). Therefore, the present study assessed whether CCR6 knockdown in HUVECs affected the function of DEPDC1. As presented in Fig. 7A and B, HUVECs incubated with TCM from DEPDC1-transfected Li-7 and Hep3B cells developed more capillary-like structures and displayed an increased invasive tendency compared with those cultured in pcDNA3.1-transfected TCM. However, CCR6 knockdown in HUVECs reversed these effects. The results therefore indicated that DEPDC1 may promote HCC progression by regulating the CCL20/CCR6 axis (Fig. 8).

**Discussion**

Previous studies have indicated that DEPDC1 is elevated in several types of cancer and is implicated in tumorigenesis (6-10). It has also been revealed that DEPDC1 is upregulated in HCC tissue and may therefore be an independent predictor of HCC (11). Furthermore, DEPDC1 was revealed to be involved in the miR-130a-induced apoptosis and inhibition of proliferation in HepG2 cells (12). Qu et al (13) revealed that DEPDC1 promoted HCC cell proliferation and neoplasm metastasis. The present study also determined that DEPDC1 was positively correlated with the K-RAS signaling pathway, certain cancer-associated pathways and the WNT/β-catenin signaling pathway. However, the mechanism of DEPDC1 in the regulation of HCC progression remains largely unknown. Therefore, further studies are required to...
assess the regulation and function of DEPDC1 to the benefit or patients with HCC. The present study determined the expression of DEPDC1 in HCC cell lines. The results revealed that DEPDC1 was significantly upregulated in HCC cell lines. However, decreased expression of DEPDC1 was detected in the normal human hepatic cells (L02). Furthermore, DEPDC1 knockdown significantly suppressed proliferation, colony formation and invasion of Huh-7 and SNU-387 cells. In addition, DEPDC1 upregulation enhanced the proliferation, colony formation
Figure 6. DEPDC1 upregulation induces tumor angiogenesis and invasion by regulating CCL20 in vitro. (A) TCM was collected from Li-7 and Hep3B cells treated with a combination of pcDNA3.1 and NC plasmids or a combination of DEPDC1 expression vectors and NC or CCL20 siRNA. A tube formation assay was performed using HUVECs with the indicated conditioned media. Scale bar, 100 µm. (B) The invasion of HUVECs was determined via a Transwell assay. Each experiment was performed in triplicate. Scale bar, 50 µm. *P<0.05, **P<0.01. DEPDC1, DEP domain containing 1; CCL20, chemokine (C-C motif) ligand 20; TCM, tumor cell-conditioned medium; NC, negative control; siRNA, small interfering RNA; HUVECs, human umbilical vein endothelial cells.
Figure 7. CCR6 knockdown in HUVECs partially reverses the effects of DEPDC1 overexpression on angiogenesis and invasion. (A) TCM was collected from Li-7 and Hep3B cells treated with pcDNA3.1 or DEPDC1 expression vectors. A tube formation assay was performed using HUVECs pretreated with NC or CCR6 siRNA with the indicated conditioned media. Scale bar, 100 µm. (B) HUVEC cell invasion was determined via a transwell assay. Each experiment was performed in triplicate. Scale bar, 50 µm. *P<0.01. CCR6, chemokine (C-C motif) receptor 6; HUVECs, human umbilical vein endothelial cells; DEPDC1, DEP domain containing 1; TCM, tumor cell-conditioned medium; NC, negative control; siRNA, small interfering RNA.
and invasion capability of Li-7 and Hep3B cells. DEPDC1 downregulation also significantly inhibited tumourigenesis in xenograft mouse models, which may be due to the inhibition of cell proliferation and colony formation. Consistent with these results, Qu et al (13) demonstrated that DEPDC1 knockdown inhibited HCC cell proliferation, colony formation, migration and invasion. In addition, DEPDC1 silencing via siRNA reduced the viability and invasion capability of prostate cancer cell lines (24), while DEPDC1 upregulation promoted prostate cancer cell proliferation and metastases (25). Collectively, the data indicated that DEPDC1 may serve an important oncogenic role in HCC progression.

To elucidate the underlying molecular mechanism of DEPDC1 in the regulation of HCC progression, gene microarray analysis was performed. GO analysis results revealed that differentially expressed genes induced by DEPDC1 knockdown were enriched in C-X-C chemokine binding, vasculature development, blood vessel development and the extracellular matrix. KEGG pathway analysis revealed that differentially expressed genes induced by DEPDC1 knockdown were significantly enriched in cytokine-cytokine receptor interactions. Gene microarray data also demonstrated that genes associated with cytokine-cytokine receptor interactions, such as CCL20 and CCR6, were significantly downregulated in Huh-7 cells transfected with DEPDC1 siRNA. CCL20 and its physiological sole receptor, CCR6, have been determined to be involved in the proliferation and metastasis of normal cells and tumor cells (23,26-31). For instance, in breast epithelial cells, CCL20/CCR6 increased cell migration via protein kinase C-ε-activate Src, thereby inducing the activation of Akt, JNK, and NF-kB pathways, and inducing cell proliferation via the ERK1/2/mitogen-activated protein kinase pathway (23). In colorectal cancer cells, CCL20/CCR6 induced cell proliferation and migration by activating of ERK1/2, stress-activated protein kinase/JNK and Akt signaling (26). In addition, CCL20 and CCR6 have been demonstrated to be upregulated in HCC tissue (15,32), and a high expression of CCL20 was associated with poorer survival and recurrence-free survival rates (33). Furthermore, the CCL20/CCR6 axis induced HCC cell proliferation, adhesion and chemotactic migration (14). The CCL20/CCR6 axis also contributes to hepatic angiogenesis in HCV-associated HCC (16). Active angiogenesis and metastasis are responsible for poor patient survival rates and the rapid recurrence of HCC (34). In the present study, RT-qPCR and western blotting revealed that DEPDC1 downregulation significantly suppressed the expression of CCL20 and CCR6 mRNA, which was consistent with gene microarray data. In addition, the results of the present study demonstrated that CCL20 and CCR6 mRNA and protein expression were significantly increased in HCC tissue when compared with matched adjacent normal liver tissue, and were positively correlated with the expression of DEPDC1. These results indicated that the CCL20/CCR6 axis may be an important intermediary of DEPDC1-mediated HCC progression. To verify this hypothesis, CCL20 protein was inhibited via CCL20 siRNA in HCC cells pretreated with the DEPDC1 expression vector. The results revealed that CCL20 knockdown reversed the effects of DEPDC1 overexpression on the cell proliferation, colony
formation and invasion of HCC cells. Furthermore, CCR6 knockdown via siRNA also rescued the effects of DEPDC1 overexpression on HCC cell proliferation, colony formation and invasion. In normal breast cells, the CCL20/CCR6 axis is known to induce the expression of cell cycle-associated proteins (c-myc, c-Fos and cyclin E1) by activating the PI3K/Akt pathway. The present study revealed that DEPDC1 upregulation induced the expression of p-Akt, c-myc and cyclin E1, while CCL20 or CCR6 knockdown reversed these effects. Thus, the results of the present study indicated that DEPDC1 promoted HCC cell proliferation, colony formation and invasion by regulating the CCL20/CCR6 axis. In addition, the present study demonstrated that DEPDC1 overexpression resulted in the enhanced angiogenesis and invasion of HCC cells. Conversely, CCL20 knockdown was revealed to reverse the effects of DEPDC1 overexpression. It has been previously demonstrated that CCL20 induces HUVEC blood vessel formation and invasion by mediating endothelial CCR6 (16). Thus, the present study hypothesized that endothelial CCR6 may be critical for DEPDC1-CCL20-angiogenesis. To confirm this, CCR6 expression was inhibited in HUVECs. The results revealed that CCR6 knockdown reversed the effects of DEPDC1 overexpression on angiogenesis and invasion of HUVECs. These results indicated that activation of CCL20/CCR6 axis induced by DEPDC1 may be one of the mechanisms that underlie DEPDC1-mediated HCC progression.

In conclusion, the present study confirmed the effect of DEPDC1 in HCC cell proliferation, colony formation and invasion. Furthermore, the results revealed that DEPDC1 promoted HUVEC angiogenesis and invasion. DEPDC1-mediated HCC progression was also determined to be at least partially dependent on the CCL20/CCR6 axis. The results of the present study may provide a new prospective on the role and mechanism of DEPDC1 in HCC.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81802398).

Availability of data and materials

The datasets used and analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

WG, ZW and SY designed the present study. WG, HLi and HLIu performed the IHC and the RT-qPCR examinations of clinical tissues. HLi and WG collected patient samples and patient information and performed the statistical analysis and the interpretation of the clinical data. WG, HLIu and XM performed the cell experiments and animal experiments and contributed to the statistical analysis and the interpretation of the data. WG wrote the manuscript. ZW and SY reviewed and edited the manuscript. ZW and SY supervised the work of the research group. All authors read and approved the final version of the manuscript.

Ethics approval and consent to participate

The present study was approved by the Ethical Committee of the First Affiliated Hospital of Chongqing Medical University (Chongqing, China). All patients provided written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.